Reply

Jacinta A. Holmes, Gail V. Matthews, Alexander J. Thompson, on behalf of the CHARIOT Study Group – 10 June 2014

Stage of cirrhosis predicts the risk of liver‐related death in patients with low model for End‐Stage liver disease scores and cirrhosis awaiting liver transplantation

Joel Wedd, Kiran M. Bambha, Matt Stotts, Heather Laskey, Jordi Colmenero, Jane Gralla, Scott W. Biggins – 10 June 2014 – The Model for End‐Stage Liver Disease (MELD) score has reduced predictive ability in patients with cirrhosis and MELD scores ≤ 20. We aimed to assess whether a 5‐stage clinical model could identify liver transplantation (LT) candidates with low MELD scores who are at increased risk for death. We conducted a case‐control study of subjects with cirrhosis and MELD scores ≤ 20 who were awaiting LT at a single academic medical center between February 2002 and May 2011.

Vasodilator‐stimulated phosphoprotein promotes activation of hepatic stellate cells by regulating Rab11‐dependent plasma membrane targeting of transforming growth factor beta receptors

Kangsheng Tu, Jiachu Li, Vikas K. Verma, Chunsheng Liu, Daniel D. Billadeau, Georg Lamprecht, Xiaoyu Xiang, Luyang Guo, Renumathy Dhanasekaran, Lewis R. Roberts, Vijay H. Shah, Ningling Kang – 10 June 2014 – Liver microenvironment is a critical determinant for development and progression of liver metastasis. Under transforming growth factor beta (TGF‐β) stimulation, hepatic stellate cells (HSCs), which are liver‐specific pericytes, transdifferentiate into tumor‐associated myofibroblasts that promote tumor implantation (TI) and growth in the liver.

Prevention of portal hypertension: From variceal development to clinical decompensation

Julio D. Vorobioff, Roberto J. Groszmann – 9 June 2014 – Pharmacological treatment of portal hypertension (PH) has been exclusively devoted to gastroesophageal varices–related events at different frameworks, including prophylactic, emergency, or preventive therapy. The goals of treatment are to avoid the first bleeding episode, stop active bleeding, and prevent bleeding recurrence, respectively. The objective of preprimary prophylaxis (PPP) is to avoid variceal development, and therefore it necessarily deals with patients with cirrhosis at earlier stages of the disease.

Prevention of portal hypertension: From variceal development to clinical decompensation

Julio D. Vorobioff, Roberto J. Groszmann – 9 June 2014 – Pharmacological treatment of portal hypertension (PH) has been exclusively devoted to gastroesophageal varices–related events at different frameworks, including prophylactic, emergency, or preventive therapy. The goals of treatment are to avoid the first bleeding episode, stop active bleeding, and prevent bleeding recurrence, respectively. The objective of preprimary prophylaxis (PPP) is to avoid variceal development, and therefore it necessarily deals with patients with cirrhosis at earlier stages of the disease.

Subscribe to